Olympus, Cangen to Co-develop 'Hybrid' DNA/Protein Microarray-based Test for Lung Cancer
Cangen Biotechnologies and Olympus plan to co-develop a hybrid DNA- and protein-based diagnostic that can detect early-stage lung cancer, the firms said this week.
The alliance will provide Cangen access to Olympus' microarray technology to enable the DNA-based portion of the test. Terms also call for Olympusto "refine" and "further develop" its microarray technology to help Cangen develop the hybrid test. Technical details were not disclosed.